blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3303400

EP3303400 - CELL-BASED ASSAY FOR DETECTING ANTI-CD3 HOMODIMERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.07.2021
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  07.08.2020
FormerGrant of patent is intended
Status updated on  29.03.2020
FormerExamination is in progress
Status updated on  25.01.2019
FormerRequest for examination was made
Status updated on  09.03.2018
FormerThe international publication has been made
Status updated on  02.12.2016
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
[2018/15]
Inventor(s)01 / CAREY, Kendall
545 Miller Avenue, Apt. No.5
South San Francisco, CA 94080 / US
 [2020/37]
Former [2018/15]01 / CAREY, Kendall
c/o Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990 / US
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2020/37]
Former [2018/15]Denison, Christopher Marcus
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date16732377.327.05.2016
[2018/15]
WO2016US34868
Priority number, dateUS201562167761P28.05.2015         Original published format: US 201562167761 P
[2018/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016191750
Date:01.12.2016
Language:EN
[2016/48]
Type: A1 Application with search report 
No.:EP3303400
Date:11.04.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.12.2016 takes the place of the publication of the European patent application.
[2018/15]
Type: B1 Patent specification 
No.:EP3303400
Date:09.09.2020
Language:EN
[2020/37]
Search report(s)International search report - published on:EP01.12.2016
ClassificationIPC:C07K16/28, C07K16/46, C12N5/0783, G01N33/50, G01N33/68
[2018/15]
CPC:
C07K16/2809 (EP,IL,KR,US); G01N33/505 (EP,IL,KR,US); G01N33/68 (IL,KR);
G01N33/6854 (IL,KR,US); C07K16/2887 (EP,IL,KR,US); C12N5/0636 (EP,IL,KR,US);
C12Q1/6897 (IL,KR); G01N33/6845 (EP,IL,KR,US); C07K2317/31 (EP,IL,KR,US);
C07K2317/56 (IL,KR,US); C07K2317/92 (IL,KR,US); C12N2510/00 (EP,IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/15]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZELLENBASIERTES TESTVERFAHREN ZUM NACHWEIS VON ANTI-CD3-HOMODIMEREN[2020/15]
English:CELL-BASED ASSAY FOR DETECTING ANTI-CD3 HOMODIMERS[2018/15]
French:TEST CELLULAIRE DE DÉTECTION D'HOMODIMÈRES ANTI-CD3[2020/15]
Former [2018/15]ZELLBASIERTER TEST ZUM NACHWEIS VON ANTI-CD3-HOMODIMEREN
Former [2018/15]ESSAI À BASE DE CELLULES POUR DÉTECTER DES HOMODIMÈRES ANTI-CD3
Entry into regional phase15.12.2017National basic fee paid 
15.12.2017Designation fee(s) paid 
15.12.2017Examination fee paid 
Examination procedure13.12.2017Date on which the examining division has become responsible
15.12.2017Examination requested  [2018/15]
09.08.2018Amendment by applicant (claims and/or description)
25.01.2019Despatch of a communication from the examining division (Time limit: M06)
05.06.2019Reply to a communication from the examining division
30.03.2020Communication of intention to grant the patent
03.08.2020Fee for grant paid
03.08.2020Fee for publishing/printing paid
03.08.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20190490.1  / EP3795679
Opposition(s)10.06.2021No opposition filed within time limit [2021/33]
Fees paidRenewal fee
07.05.2018Renewal fee patent year 03
08.05.2019Renewal fee patent year 04
30.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.05.2016
AL09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
MT09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
LU27.05.2021
[2024/42]
Former [2024/22]HU27.05.2016
AL09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
MK09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
LU27.05.2021
Former [2023/30]HU27.05.2016
AL09.09.2020
CY09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
LU27.05.2021
Former [2023/29]HU27.05.2016
AL09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
LU27.05.2021
Former [2022/09]AL09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
LU27.05.2021
Former [2022/07]AL09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
MC09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/37]AL09.09.2020
CZ09.09.2020
DK09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/28]AL09.09.2020
CZ09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
SK09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/25]AL09.09.2020
CZ09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
IS09.01.2021
PT11.01.2021
Former [2021/23]CZ09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
SM09.09.2020
BG09.12.2020
NO09.12.2020
PT11.01.2021
Former [2021/22]CZ09.09.2020
EE09.09.2020
FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
BG09.12.2020
NO09.12.2020
PT11.01.2021
Former [2021/21]FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
BG09.12.2020
NO09.12.2020
PT11.01.2021
Former [2021/10]FI09.09.2020
LT09.09.2020
LV09.09.2020
RS09.09.2020
BG09.12.2020
NO09.12.2020
Former [2021/08]FI09.09.2020
LT09.09.2020
BG09.12.2020
NO09.12.2020
Former [2021/07]FI09.09.2020
LT09.09.2020
NO09.12.2020
Cited inInternational search[A] WO2014047231  (REGENERON PHARMA et al.)
 [XYI]   STEL A. ET AL.: "The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3", J. IMMUNOL., vol. 173, no. 10, November 2004 (2004-11-01), pages 6009 - 6016, XP055089413

DOI:   http://dx.doi.org/10.4049/jimmunol.173.10.6009
 [Y]   SUN L.L. ET AL.: "Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies", SCI. TRANSLAT. MED., vol. 7, no. 287, 287RA70, 13 May 2015 (2015-05-13), pages 1 - 10, XP055241859

DOI:   http://dx.doi.org/10.1126/scitranslmed.aaa4802
 [Y]   BRISCHWEIN K. ET AL.: "Strictly target cell dependent activation of T cells by bispecific single chain antibody constructs of the Bite Class", J. IMMUNOTHER., vol. 30, no. 8, November 2007 (2007-11-01), pages 798 - 807, XP055276936

DOI:   http://dx.doi.org/10.1097/CJI.0b013e318156750c
 [A]   JUNTTILA T.T. ET AL.: "Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells", CANCER RES., vol. 74, no. 19, October 2014 (2014-10-01), pages 5561 - 5571, XP055216350

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
by applicantUS5641870
 EP0404097
 WO9311161
 WO9308829
 US5731168
 WO2009089004
 US4676980
 WO2005035572
 WO03035694
 WO0029004
 WO02051870
 US4816567
 US5693780
 US5500362
 US5821337
 WO9411026
 US5534615
 US5648237
 US5789199
 US5840523
 US7521541
 US5591669
 US5589369
 US5545807
 US5565332
 US5573905
 US5567610
 US5229275
 WO9316185
 US5571894
 US5587458
 WO9404690
 WO9100360
 WO9220373
 EP0308936
 US2006067930
 US5208020
 US5712374
   KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
   CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   ZAPATA ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062
   PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315
   HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
   MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537
   TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655
   BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
   KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
   GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368
   TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
   WARD, ES ET AL., NATURE, vol. 341, 1989, pages 544 - 546
   DOOLEY, H. ET AL., DEV COMP IMMUNOL, vol. 30, 2006, pages 43 - 56
   MUYLDEMANS S ET AL., TREND BIOCHEM SCI, vol. 26, 2001, pages 230 - 235
   HOLT, LJ ET AL., TRENDS BIOTECHNOL, vol. 21, 2003, pages 484 - 490
   DAVIES, J ET AL., FEBS LETT, vol. 339, 1994, pages 285 - 290
   KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
   CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
   MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
   PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
   RAVETCH; KINET, ANNU. REV. IMMUNOL, vol. 9, 1991, pages 457 - 92
   CLYNES ET AL., PROC. NATL. ACAD. SCI. (USA), vol. 95, 1998, pages 652 - 656
   DARON, ANNU. REV. IMMUNOL., vol. 15, 1997, pages 203 - 234
   CAPEL ET AL., IMMUNOMETHODS, vol. 4, 1994, pages 25 - 34
   DE HAAS ET AL., J. LAB. CLIN. MED., vol. 126, 1995, pages 330 - 41
   GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587
   KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249
   DE GAST GC ET AL., CANCER IMMUNOL IMMUNOTHER, vol. 40, no. 6, 1995, pages 390 - 396
   BUHMANN R ET AL., BONE MARROW TRANSPLANT., vol. 43, no. 5, 2009, pages 383 - 397
   CHAN JK ET AL., CLIN CANCER RES., vol. 12, no. 6, 2006, pages 1859 - 1867
   CHAMES, P.; BATY, D., MABS, vol. 1, no. 6, 2009, pages 539 - 547
   FOURNIER, P.; SCHIRRMACHER, V., BIODRUGS, vol. 27, no. 1, 2013, pages 35 - 53
   ZWEIFACH A, IMMUNOL REV., vol. 231, no. 1, 2009, pages 160 - 173
   PIPKIN, ME ET AL., IMMUNOL REV., vol. 235, no. 1, 2010, pages 55 - 72
   PARDO, J ET AL., INT IMMUNOL., vol. 15, no. 12, 2003, pages 1441 - 1450
   KROGSGAARD M ET AL., SEMIN IMMUNOL, vol. 15, no. 6, 2003, pages 307 - 315
   PATTU V ET AL., FRONT IMMUNOL., vol. 4, 2013, pages 411
   KLIEGER Y ET AL., EUR J IMMUNOL., vol. 44, no. 1, 2014, pages 58 - 68
   SCHWARTZ JC ET AL., NAT IMMUNOL., vol. 3, no. 5, 2002, pages 427 - 434
   BROWN, WM, CURR OPIN INVESTIG DRUGS, vol. 7, 2006, pages 381 - 388
   FERRAN, C ET AL., EXP NEPHROL, vol. 1, 1993, pages 83 - 89
   MF ET AL., J. LEUKOC. BIOL., vol. 57, 1995, pages 767 - 773
   SHAPIRO VS ET AL., J. IMMUNOL., vol. 161, no. 12, 1998, pages 6455 - 6458
   SHANNON, MF ET AL., J. LEUKOC. BIOL., vol. 57, 1995, pages 767 - 773
   BROGAN J ET AL., RADIAT RES., vol. 177, no. 4, 2012, pages 508 - 513
   MIRAGLIA LJ ET AL., COMB CHEM HIGH THROUGHPUT SCREEN., vol. 14, no. 8, 2011, pages 648 - 657
   NAKAJIMA Y; OHMIYA Y, EXPERT OPIN DRUG DISCOVERY, vol. 5, no. 9, 2010, pages 835 - 849
   PAREKH BS ET AL., MABS, vol. 4, no. 3, 2012, pages 310 - 318
   SVOBODOVA K; CAJTHAM L T., APPL MICROBIOL BIOTECHNOL., vol. 88, no. 4, 2010, pages 839 - 847
   OSAKA, G ET AL., J PHARM SCI., vol. 85, 1996, pages 612 - 618
   NAKAMURA, GR ET AL., J. VIROL., vol. 67, no. 10, 1993, pages 6179 - 6191
   NALDINI, L. ET AL., SCIENCE, vol. 272, 1996, pages 263 - 267
   CHARLTON: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254
   CARTER ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 163 - 167
   GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
   KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
   BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", 1987, MARCEL DEKKER, INC., pages: 51 - 63
   MUNSON ET AL., ANAL. BIOCHEM., vol. 107, 1980, pages 220
   SKERRA ET AL., CURR. OPINION IN IMMUNOL., vol. 5, 1993, pages 256 - 262
   PLC THUN, IMMUNOL. REVS., vol. 130, 1992, pages 151 - 188
   MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554
   MARKS ET AL., BIOLTECHNOLOGY, vol. 10, 1992, pages 779 - 783
   WATERHOUSE ET AL., NUC. ACIDS. RES., vol. 21, 1993, pages 2265 - 2266
   MORRISON ET AL., PROC. NATL ACAD. SCI. USA, vol. 81, 1984, pages 6851
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296
   CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901
   CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285
   PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623
   JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 2551
   JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
   BRUGGERMANN ET AL., YEAR IN IMMUNO, vol. 7, 1993, pages 33
   MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 553
   JOHNSON, KEVIN S.; CHISWELL, DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, vol. 3, 1993, pages 564 - 571
   GRIFFITH ET AL., EMBO J., vol. 12, 1993, pages 725 - 734
   MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
   CARTER ET AL., BIOL1'ECHNOLOGY, vol. 10, 1992, pages 163 - 167
   MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
   TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
   SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210
   CARON ET AL., J. EXP MED., vol. 176, 1992, pages 1191 - 1195
   SHOPES, B. J., IMMUNOL, vol. 148, 1992, pages 2918 - 2922
   WOLFF ET AL., CANCER RESEARCH, vol. 53, 1993, pages 2560 - 2565
   STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, vol. 3, 1989, pages 219 - 230
   CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
   A. L. LEHNINGER: "Biochemistry", 1975, WORTH PUBLISHERS, pages: 73 - 75
   VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098
   GENNARO, A.R.,: "Remington's Pharmaceutical Sciences, 18th edition,", 1990
   SHIPKOVA M, CLIN. CHIM. ACTA, vol. 413, 2012, pages 1338 - 49
   ZIEGLER SF, ET AL., STEM CELLS, vol. 12, no. 5, 1994, pages 465 - 465
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.